The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days

Contraception

Volumn 73, Issue 1, 2006, Pages 34-40

  Foidart, Jean Michel ^a   Sulak, Patricia J ^b,c   Schellschmidt, Ilka ^d   Zimmermann, Doris ^d  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c TEXAS A M COLLEGE OF MEDICINE   (United States)

^d BAYER PHARMA AG   (Germany)

Author keywords

Breakthrough bleeding; Drospirenone; Endometrial safety; Extended cycle; Oral contraceptive

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAKTHROUGH BLEEDING; CHOLELITHIASIS; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG INDUCED HEADACHE; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM BIOPSY; FEMALE; FLU LIKE SYNDROME; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTALGIA; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; MULTICENTER STUDY; PATIENT SATISFACTION; PHARYNGITIS; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; SINUSITIS;

ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; PATIENT SATISFACTION; PROSPECTIVE STUDIES; TIME FACTORS; UTERINE HEMORRHAGE;

EID: 29144505118     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2005.06.068     Document Type: Article

References (21)

1. G. Pincus, C.R. Garcia, and J. Rock Effectiveness of an oral contraceptive; effects of a progestin-estrogen combination upon fertility, menstrual phenomena, and health Science 130 1959 81 83
2. S.L. Thomas, and C. Ellertson Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 355 2000 922 924
3. N.B. Loudon, M. Foxwell, D.M. Potts, A.L. Guild, and R.V. Short Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen BMJ 2 1977 487 490
4. J. Shakespeare, E. Neve, and K. Hodder Is norethisterone a lifestyle drug? Results of database analysis BMJ 320 2000 291
5. F.D. Anderson, and H. Hait A multicenter, randomized study of an extended cycle oral contraceptive Contraception 68 2003 89 96
6. M. Kwiecien, A. Edelman, M.D. Nichols, and J.T. Jensen Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial Contraception 67 2003 9 13
7. L. Miller, and J.P. Hughes Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial Obstet Gynecol 101 2003 653 661
8. U.S. Food and Drug Administration Drug approval package for Seasonale (levonorgestrel/ethinyl estradiol) tablets (created 03/24/2004) Internet Commun 2004 http://www.fda.gov/cder/foi/nda/2003/21-544_Seasonale.htm
9. P.J. Sulak, T.J. Kuehl, M. Ortiz, and B.L. Shull Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms Am J Obstet Gynecol 186 2002 1142 1149
10. P.J. Sulak, J. Carl, I. Gopalakrishnan, A. Coffee, and T.J. Kuehl Outcomes of extended oral contraceptive regimens with a shortened hormone-free interval to manage breakthrough bleeding Contraception 70 2004 281 287
11. I. den Tonkelaar, and B.J. Oddens Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use Contraception 59 1999 357 362
12. U.S. Food and Drug Administration Birth control guide (Updated December 2003) FDA Consum 2004 http://www.fda.gov/fdac/features/1997/babytabl.html
13. J.M. Foidart, W. Wuttke, G.M. Bouw, C. Gerlinger, and R. Heithecker A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel Eur J Contracept Reprod Health Care 5 2000 124 134
14. J. Huber, J.M. Foidart, and W. Wuttke Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone Eur J Contracept Reprod Health Care 5 2000 25 34
15. K.S. Parsey, and A. Pong An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen Contraception 61 2000 105 111
16. H. Thorneycroft, H. Gollnick, and I. Schellschmidt Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment Cutis 74 2004 123 130
17. W.A. van Vloten, C.W. van Haselen, E.J. van Zuuren, C. Gerlinger, and R. Heithecker The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea Cutis 69 2002 2 15
18. E.M. Belsey, D. Machin, and C. d'Arcangues The analysis of vaginal bleeding patterns induced by fertility regulating methods. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction Contraception 34 1986 253 260
19. P.J. Sulak, B.E. Cressman, E. Waldrop, S. Holleman, and T.J. Kuehl Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms Obstet Gynecol 89 1997 179 183
20. P. Coney, and A. DelConte The effects on ovarian activity of a monophasic oral contraceptive with 100 microg levonorgestrel and 20 microg ethinyl estradiol Am J Obstet Gynecol 181 1999 53 58
21. F. Ludicke, E. Johannisson, and F.M. Helmerhorst Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 microg of ethinyl estradiol on the human endometrium Fertil Steril 76 2001 102 107